BioSpace News Archive

TAE Life Sciences, a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions, announced that Bruce Bauer, Chief Executive Officer, will present a corporate overview at the Summer 2020 Private Company Showcase, hosted by Solebury Trout, on August 10, 2020.

Tangen Biosciences, Inc., a molecular diagnostic company located in Branford, Connecticut, announced that it has closed a $12.2 million Series B Preferred Stock financing with participation of current and new investors, including Connecticut Innovations, VC23, Leading Edge Ventures, and Parvizi Surgical. The financing was oversubscribed from the $10 million initial

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support efforts to broaden visibility within the US capital markets. “We are excited to have engaged Stern IR as our new investor relations firm to support us in enhancing our visibility within the US clinical and financial communities,” said

New data indicate stable kidney function across the two Fabry disease clinical studies up to 32 months New six-month Phase 2 FAB-201 data from first patient treated using AVROBIO’s plato ® gene therapy platform show continued reduction in toxic metabolite plasma lyso-Gb3 and increased leukocyte and plasma enzyme activity Sustained clinical data across multiple other measures for Phase 1 and Phase 2 trials for Fabry disease First patient h

– Company Targeting Enrollment Completion for Pivotal PHYOX™2 Trial of Nedosiran in Fourth Quarter 2020 – – Company Reported $669.2 Million in Cash, Cash Equivalents and Marketable Securities as of June 30, 2020 – – Management to Host Virtual R&D Day Event Today at 10:00 a.m. ET – LEXINGTON, Mass.--( BUSINESS WIRE )-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational r

– In the Ongoing Phase 1 Proof-of-Concept Trial Multidose Group, RG6346 1.5, 3.0 and 6.0 mg/kg Dosing Cohorts Reached Mean HBsAg Reduction From Baseline of 1.39, 1.80 and 1.84 Log10 IU/mL, Respectively, at Day 112 End-of-Treatment; Data for Earliest-Dose Cohort of 1.5 mg/kg Showed Durability of Response Through Day 336 – – Self-Resolving ALT Elevations With Preserved Liver Function in Several Participants Treated With RG6346 Suggest ALT Flares Potential

New Drug Application for Epsolay® Submitted; Twyneo® New Drug Application on track for 2H 2020 Top-line generic product revenue of $1.1 million in 2Q 2020 Launch of additional generic product expected in 2Q 2021 NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today

Ortho Regenerative Technologies Inc. an emerging orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced that Ortho-R is designated as a Drug/Biologic combination product, by the FDA Office for Combination Products.

Current independent tests have confirmed that BioSafe Defenses’ patented antimicrobial compounds kill Covid-2 the virus that is the precursor to and causes COVID-19.

Reports Flat Revenue of $1.5 Billion, and Net Income of $377 Million, or $0.79 per Diluted Share, Increasing 2% and 3%, Respectively, on a Reported Basis for Second Quarter 2020 Reports Adjusted Net Income of $427 Million, or Adjusted Diluted EPS of $0.89 for Second Quarter 2020 Delivers 4% Operational Growth in Revenue and 4% Operational Growth in Adjusted Net Income for Second Quarter 2020 Raises and Narrows Full Year 2020 Reven